Elizabeth D. Krell Sells 10,000 Shares of AtriCure Inc. (ATRC) Stock
AtriCure Inc. (NASDAQ:ATRC) Director Elizabeth D. Krell sold 10,000 shares of the business’s stock in a transaction dated Tuesday, November 15th. The stock was sold at an average price of $19.73, for a total value of $197,300.00. Following the completion of the transaction, the director now owns 24,162 shares in the company, valued at approximately $476,716.26. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
AtriCure Inc. (NASDAQ:ATRC) opened at 19.31 on Friday. The stock’s 50 day moving average price is $17.37 and its 200 day moving average price is $15.66. AtriCure Inc. has a 12-month low of $13.44 and a 12-month high of $23.24. The company’s market capitalization is $641.85 million.
AtriCure (NASDAQ:ATRC) last issued its quarterly earnings results on Thursday, October 27th. The medical device company reported ($0.21) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.28) by $0.07. The company had revenue of $38.34 million for the quarter, compared to the consensus estimate of $10.75 million. AtriCure had a negative return on equity of 19.84% and a negative net margin of 23.78%. The firm’s revenue was up 22.1% compared to the same quarter last year. During the same period last year, the business posted ($0.22) earnings per share. On average, equities research analysts anticipate that AtriCure Inc. will post ($1.10) earnings per share for the current fiscal year.
Several research analysts recently commented on ATRC shares. Zacks Investment Research upgraded AtriCure from a “hold” rating to a “strong-buy” rating and set a $21.00 price target on the stock in a research note on Tuesday, November 1st. BTIG Research restated a “buy” rating and set a $19.00 price objective (down previously from $34.00) on shares of AtriCure in a research note on Wednesday, August 10th. Needham & Company LLC restated a “buy” rating and set a $20.00 price objective (down previously from $23.00) on shares of AtriCure in a research note on Monday, August 8th. Stifel Nicolaus cut their price objective on AtriCure from $26.00 to $21.00 and set a “buy” rating on the stock in a research note on Friday, August 5th. Finally, Piper Jaffray Cos. restated an “overweight” rating and set a $17.00 price objective (down previously from $22.00) on shares of AtriCure in a research note on Monday, August 8th. One analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $20.75.
Large investors have recently modified their holdings of the stock. Dynamic Technology Lab Private Ltd acquired a new stake in shares of AtriCure during the second quarter valued at about $298,000. Vanguard Group Inc. increased its stake in shares of AtriCure by 7.5% in the second quarter. Vanguard Group Inc. now owns 1,216,110 shares of the medical device company’s stock valued at $17,183,000 after buying an additional 84,953 shares in the last quarter. SECOR Capital Advisors LP acquired a new stake in shares of AtriCure during the second quarter valued at about $749,000. Nationwide Fund Advisors increased its stake in shares of AtriCure by 11.8% in the second quarter. Nationwide Fund Advisors now owns 20,424 shares of the medical device company’s stock valued at $289,000 after buying an additional 2,152 shares in the last quarter. Finally, Royce & Associates LP increased its stake in shares of AtriCure by 44.8% in the second quarter. Royce & Associates LP now owns 480,300 shares of the medical device company’s stock valued at $6,787,000 after buying an additional 148,500 shares in the last quarter. 83.09% of the stock is currently owned by institutional investors.
AtriCure Company Profile
AtriCure, Inc is a medical device company providing atrial fibrillation (Afib) solutions. The Company’s segment develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. The Company has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures.
Receive News & Stock Ratings for AtriCure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure Inc. and related stocks with our FREE daily email newsletter.